Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
SUVEN LIFE SCIENCES TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SUVEN LIFE SCIENCES Mar-23 |
TEVA PHARMA Dec-13 |
SUVEN LIFE SCIENCES/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 94 | 3,477 | - | |
Low | Rs | 45 | 3,020 | - | |
Sales per share (Unadj.) | Rs | 0.6 | 1,995.2 | - | |
Earnings per share (Unadj.) | Rs | -5.4 | 124.6 | - | |
Cash flow per share (Unadj.) | Rs | -5.1 | 285.9 | - | |
Dividends per share (Unadj.) | Rs | 0 | 109.11 | - | |
Avg Dividend yield | % | 0 | 3.4 | 0.0% | |
Book value per share (Unadj.) | Rs | 17.2 | 2,216.3 | - | |
Shares outstanding (eoy) | m | 218.07 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 111.8 | 1.6 | 6,864.5% | |
Avg P/E ratio | x | -12.8 | 26.1 | -49.1% | |
P/CF ratio (eoy) | x | -13.5 | 11.4 | -119.2% | |
Price / Book Value ratio | x | 4.0 | 1.5 | 275.1% | |
Dividend payout | % | 0 | 87.5 | -0.0% | |
Avg Mkt Cap | Rs m | 15,131 | 2,754,567 | 0.5% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 186 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,645.0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,351.7 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 135 | 1,691,953 | 0.0% | |
Other income | Rs m | 84 | 0 | - | |
Total revenues | Rs m | 220 | 1,691,953 | 0.0% | |
Gross profit | Rs m | -1,196 | 463,342 | -0.3% | |
Depreciation | Rs m | 65 | 136,762 | 0.0% | |
Interest | Rs m | 5 | 33,233 | 0.0% | |
Profit before tax | Rs m | -1,183 | 293,347 | -0.4% | |
Minority Interest | Rs m | 0 | 1,333 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -192,566 | -0.0% | |
Tax | Rs m | 0 | -3,581 | -0.0% | |
Profit after tax | Rs m | -1,183 | 105,695 | -1.1% | |
Gross profit margin | % | -883.6 | 27.4 | -3,226.7% | |
Effective tax rate | % | 0 | -1.2 | 0.0% | |
Net profit margin | % | -873.5 | 6.2 | -13,983.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 3,455 | 1,142,739 | 0.3% | |
Current liabilities | Rs m | 1,050 | 996,565 | 0.1% | |
Net working cap to sales | % | 1,776.0 | 8.6 | 20,557.4% | |
Current ratio | x | 3.3 | 1.1 | 286.9% | |
Inventory Days | Days | 3,948 | 91 | 4,348.6% | |
Debtors Days | Days | 218 | 96 | 226.9% | |
Net fixed assets | Rs m | 1,373 | 552,629 | 0.2% | |
Share capital | Rs m | 218 | 4,165 | 5.2% | |
Net worth | Rs m | 3,753 | 1,879,439 | 0.2% | |
Long term debt | Rs m | 0 | 865,133 | 0.0% | |
Total assets | Rs m | 4,828 | 3,866,655 | 0.1% | |
Interest coverage | x | -218.8 | 9.8 | -2,226.8% | |
Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
Sales to assets ratio | x | 0 | 0.4 | 6.4% | |
Return on assets | % | -24.4 | 3.6 | -678.7% | |
Return on equity | % | -31.5 | 5.6 | -560.3% | |
Return on capital | % | -31.4 | 4.9 | -636.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | -1,031 | 269,610 | -0.4% | |
From Investments | Rs m | -2,606 | -95,534 | 2.7% | |
From Financial Activity | Rs m | 3,955 | -323,415 | -1.2% | |
Net Cashflow | Rs m | 317 | -149,339 | -0.2% |
Compare SUVEN LIFE SCIENCES With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare SUVEN LIFE SCIENCES With: MESCO PHARMA HINDUSTAN BIOSCIE CHEMO PHARMA EVEREST ORGANICS LAURUS LABS
After opening the day on high, Indian share markets continued the momentum as the session progressed and ended the higher.